Garcia-Manero, G., McCloskey, J., Scott, B. L., Griffiths, E. A., Kiner-Strachan, B., Brunner, A. M., … Savona, M. R. (2024). Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN). In Blood (Vol. 144, pp. 662–662). American Society of Hematology. https://doi.org/10.1182/blood-2024-203569

Garcia-Manero, Guillermo, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Andrew M. Brunner, Amer M. Zeidan, et al. “Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN).” In Blood, 144:662–662. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-203569.

Garcia-Manero G, McCloskey J, Scott BL, Griffiths EA, Kiner-Strachan B, Brunner AM, et al. Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN). In: Blood. American Society of Hematology; 2024. p. 662–662.

Garcia-Manero, Guillermo, et al. “Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN).” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 662–662. Crossref, doi:10.1182/blood-2024-203569.

Garcia-Manero G, McCloskey J, Scott BL, Griffiths EA, Kiner-Strachan B, Brunner AM, Zeidan AM, Traer E, Madanat YF, Meyer J, Erba H, Baratam P, Borate U, Sano Y, Oganesian A, Zhu L, Keer HN, Savona MR. Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN). Blood. American Society of Hematology; 2024. p. 662–662.